Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection

Thrombosis and Haemostasis

Volumn 110, Issue 3, 2013, Pages 484-492

  Thorek, Daniel L J ^a   Evans, Michael J ^a   Carlsson, Sigrid V ^a,b   Ulmert, David ^a   Lilja, Hans ^a,c,d,e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANDROGEN RECEPTOR; DOXORUBICIN; KALLIKREIN; KALLIKREIN 2; KALLIKREIN INHIBITOR; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; SOMATOMEDIN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; BLOOD PRESSURE; CANCER GROWTH; CANCER MORTALITY; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HOMEOSTASIS; HUMAN; IMMUNOFLUORESCENCE; INFLAMMATION; KLK2 GENE; KLK3 GENE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EQUIPMENT DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MODELS, MOLECULAR; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, ANDROGEN; TISSUE KALLIKREINS; TRYPSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84883254543     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0275     Document Type: Review

References (76)

1. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
2. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004; 93: 233-241.
3. Siegel R, et al. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
4. Lundwall A, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-641.
5. Clements JA, et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
6. Olsson AY, et al. Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen. Genomics 2004; 84: 147-156.
7. Marques PI, et al. Birth-and-death of KLK3 and KLK2 in primates: evolution driven by reproductive biology. Genome Biol Evol 2012; 4: 1331-1338.
8. Lovgren J, et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997; 238: 549-555.
9. Lilja H, Laurell CB. The predominant protein in human seminal coagulate. Scand J Clin Lab Invest 1985; 45: 635-641.
10. Denmeade SR, et al. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 2001; 48: 122-126.
11. Lilja H, et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 281-285.
12. Lilja H, et al. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989; 264: 1894-1900.
13. Frenette G, et al. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 1997; 71: 897-899.
14. Rehault S, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001; 268: 2960-2968.
15. Cohen P, et al. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994; 142: 407-415.
16. Cohen P, et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046-1053.
17. Iwamura M, et al. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996; 48: 317-325.
18. Christensson A, et al. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-763.
19. Misra UK, et al. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem 2011; 286: 1248-1259.
20. Saraswati S, et al. Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate 2011; 71: 197-208.
21. Nangia-Makker P, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899-909.
22. Mahabeer R, Bhoola KD. Kallikrein and kinin receptor genes. Pharmacol Ther 2000; 88: 77-89.
23. Deperthes D, et al. Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Biochim Biophys Acta 1997; 1343: 102-106.
24. Fortier AH, et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003; 56: 212-219.
25. Fortier AH, et al. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635-1640.
26. Koistinen H, et al. Novel small molecule inhibitors for prostate-specific antigen. Prostate 2008; 68: 1143-1151.
27. Mattsson JM, et al. The antiangiogenic role of prostate-specific antigen. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. 2010. Washington, DC: AACR.
28. Mattsson JM, et al. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity. Prostate 2012; 72: 1588-1594.
29. Ankerst DP. Prostate cancer screening. 2nd ed2009, New York: Humana Press.
30. Stamey TA, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916.
31. Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
32. Savblom C, et al. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005; 65: 66-72.
33. Lilja H, et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-278.
34. Lilja H, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618-1625.
35. Zhang WM, et al. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate 1997; 33: 87-96.
36. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994; 220: 45-53.
37. Stenman UH, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-226.
38. Christensson A, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-105.
39. Mikolajczyk SD, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001; 61: 6958-6963.
40. Vaisanen V, et al. Characterisation and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis 1999; 2: 91-97.
41. Nurmikko P, et al. Production and characterisation of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000; 46: 1610-1618.
42. Vaisanen V, et al. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem 2006; 78: 7809-7815.
43. Nurmikko P, et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001; 47: 1415-1423.
44. Mikolajczyk SD, et al. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802.
45. Steuber T, et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007; 53: 233-240.
46. Roddam AW, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386-399.
47. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013; 51: 729-739.
48. Vickers AJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011; 20: 255-261.
49. Amarapurkur DN, Trivedi MH, Desai HG. Metoclopramide in variceal bleeding. Indian J Gastroenterol 1991; 10: 71-72.
50. de Koning HJ, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002; 97: 237-244.
51. Hugosson J, et al. Mortality results from the Goteborg randomised populationbased prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732.
52. Schroder FH, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
53. Schroder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 2010; 58: 46-52.
54. Andriole GL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
55. Gulati R, et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012; 23: 827-835.
56. Andriole GL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
57. Schroder FH, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62: 745-752.
58. Heijnsdijk EA, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605.
59. Moyer VA, U.S.P.S.T. Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
60. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2012; 10: 38-48.
61. Gomella LG, et al. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 2011; 18: 5875-5883.
62. Horwich A, et al. and Panel Members. ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013; 24: 1141-1162.
63. Nilsson PM, et al. Social mobility, marital status, and mortality risk in an adult life course perspective: the Malmo Preventive Project. Scand J Public Health 2005; 33: 412-423.
64. Ulmert D, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008; 6: 6.
65. Lilja H, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25: 431-436.
66. Lilja H, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-1219.
67. Vickers AJ, et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 2007; 121: 2212-2217.
68. LeBeau AM, et al. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem Biol 2008; 15: 665-674.
69. LeBeau AM, et al. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry 2009; 48: 3490-3496.
70. Cosgrove DM, 3rd, et al. Aprotinin therapy for reoperative myocardial revascularisation: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-1038.
71. Denmeade SR, et al. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997; 57: 4924-4930.
72. Denmeade SR, et al. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 1998; 58: 2537-2540.
73. Denmeade SR, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95: 990-1000.
74. Ulmert D, et al. Imaging androgen receptor signalling with a radiotracer targeting free prostate-specific antigen. Cancer Discov 2012; 2: 320-327.
75. LeBeau, AM, et al. Optimisation of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorg Med Chem 2009; 17: 4888-4893.
76. Miyamoto DT, et al. Androgen receptor signalling in circulating tumour cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012; 2: 995-1003.